16.12.2022 13:58:30
|
Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi (SNY) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Dupixent (dupilumab) in the European Union to treat adults and adolescents with eosinophilic esophagitis or EoE.
CHMP's positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not candidates for conventional medicinal therapy.
The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with EoE in the EU.
In May 2022, the U.S. Food and Drug Administration approved Dupixent 300 mg weekly for the treatment of patients aged 12 years and older, weighing at least 40 kg.
EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. For people with EoE, swallowing even small amounts of food can be a painful and worrisome choking experience.
The companies noted that the CHMP's positive opinion is based on pivotal trial data demonstrating patients on Dupixent 300 mg weekly experienced significantly improved ability to swallow and achieved histological disease remission compared to placebo.
For More Such Health News, visit rttnews.com
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.mehr Nachrichten
19.12.24 |
Starker Wochentag in New York: NASDAQ 100-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
18.12.24 |
NASDAQ Composite Index-Wert Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte ein Regeneron Pharmaceuticals-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
17.12.24 |
Schwacher Handel: NASDAQ 100 letztendlich im Minus (finanzen.at) | |
17.12.24 |
Handel in New York: NASDAQ 100 gibt am Nachmittag nach (finanzen.at) | |
17.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 fällt am Dienstagmittag zurück (finanzen.at) | |
12.12.24 |
Börse New York: NASDAQ 100 schwächelt zum Ende des Donnerstagshandels (finanzen.at) | |
12.12.24 |
Schwacher Handel in New York: NASDAQ 100 verliert am Donnerstagnachmittag (finanzen.at) | |
12.12.24 |
Zurückhaltung in New York: NASDAQ 100 fällt am Mittag (finanzen.at) |
Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Regeneron Pharmaceuticals Inc. | 672,00 | -1,06% | |
Sanofi S.A. (spons. ADRs) | 45,60 | 0,44% | |
Sanofi S.A. | 91,01 | -0,12% |